퀘이사의 팜

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.

finance.yahoo.com